Fulltext

Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group

Benard, Antoine ; van Sighem, Ard ; Taieb, Audrey ; Valadas, Emilia ; Ruelle, Jean ; Soriano, Vicente ; Calmy, Alexandra ; Balotta, Claudia ; Damond, Florence ; Brun-Vezinet, Françoise ; Chene, Geneviève ; Matheron, Sophie

In: Clinical Infectious Diseases, 2011, vol. 52, no. 10, p. 1257-1266

Zum persönliche Liste hinzufügen
    Titel
    • Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group
    Autor
    • Benard, Antoine. INSERM, U897
    • van Sighem, Ard. Stichting HIV Monitoring, Amsterdam, the Netherlands
    • Taieb, Audrey. INSERM, U897
    • Valadas, Emilia. Hospital de Santa Maria, Clinica Universitaria de Doenças Infecciosas, Lisbon, Portugal
    • Ruelle, Jean. Université Catholique de Louvain, AIDS Reference Laboratory, Brussels, Belgium
    • Soriano, Vicente. Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    • Calmy, Alexandra. Hôpitaux Universitaires de Genève, Service de Maladies Infectieuses, Unite VIH/SIDA, Geneva, Switzerland
    • Balotta, Claudia. University of Milan, Department of Clinical Sciences "L. Sacco", Section of Infectious Diseases, Milan, Italy
    • Damond, Florence. APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie
    • Brun-Vezinet, Françoise. APHP, Hôpital Bichat - Claude Bernard, Laboratoire de Virologie
    • Chene, Geneviève. INSERM, U897
    • Matheron, Sophie. Paris VII Denis Diderot University
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Clinical Infectious Diseases, 2011, vol. 52, no. 10, p. 1257-1266. Oxford University Press
    Andere elektronische Ausgabe
    Klassifikation
    • Gesundheit
    Schlagwörter
    OAI-PMH-ID
    • oai:doc.rero.ch:298382
    Summary
    This European inter-cohort collaboration shows poorer immunological and virological responses with triple NRTI compared to PI/r-containing cART in treatment-naïve HIV-2-infected patients, regardless of baseline CD4 cell count. PI/r-containing cART should be recommended as first-line antiretroviral regimens in HIV-2 infection